Skip to content

Getting To Zero
20 May 2016 - 13:13

The Republic of Zimbabwe has made strides in Anti-retroviral therapy (ART) service provision and, among other interventions, has adapted the Community ART Refill Group (CARG) model which supports self-formed groups of clients, who are stable in accessing ART. The members of the groups would usually be coming from the same geographical area. The overall goal of this model is to reduce the burden and challenges for both health care workers and patients in the provision and receipt of ART and improving adherence and retention in care and treatment.

20 May 2016 - 12:11

University at Buffalo

BUFFALO, N.Y. - To train future HIV researchers, the University at Buffalo and University of Zimbabwe have partnered to form the HIV Research Training Program, supported by a $1.3 million grant from the National Institutes of Health (NIH) John E. Fogarty International Center.

The five-year grant will support doctoral candidates and postdoctoral fellows completing clinical pharmacology research at the University of Zimbabwe (UZ) Center of Excellence in Clinical Pharmacology and Pharmaceutical Sciences.

"The award will help UZ attract and train the highest talent in pharmacological research," says Charles Chiedza Maponga, PharmD, co-investigator, director of the UZ Center of Excellence in Clinical Pharmacology and Pharmaceutical Sciences, and research assistant professor in the UB School of Pharmacy and Pharmaceutical Sciences.

20 May 2016 - 12:06

20 May 2016
South Africa Info
A successful early-stage HIV vaccine clinical trial in South Africa has prompted the expansion of the experimental vaccine regimen into a large clinical trial. The new study, called HVTN 702, is designed to determine whether the regimen is safe, tolerable and effective at preventing HIV infection among South African adults. It will use a new variation of the RV144 shot, an experimental HIV vaccine developed by the US's National Institute of Allergy and Infectious Diseases (Niaid). The drug will be trialled in South Africa at the end of 2016.

The HVTN 702 study will be led by Protocol Chair Dr Glenda Gray. Gray is the president and CEO of the South African Medical Research Council, research professor of paediatrics at the University of the Witwatersrand, Johannesburg, and a director of the Perinatal HIV Research Unit at Chris Hani Baragwanath Hospital in Soweto, South Africa.

glqxz9283 sfy39587stf01